Crispr surges 21% on results of in-human study using gene-editing tool
Crispr is also studying medicines in both solid and blood cancers and is in the early stages of developing treatments for diabetes and cystic fibrosis
New York — A first in-human study using the gene-editing tool Crispr has a company named after the technology and its partner, Vertex Pharmaceuticals, claiming an early victory in treating two inherited blood disorders.
Crispr Therapeutics and Vertex said a pair of patients — one suffering from beta thalassemia and the other with severe sickle cell disease — saw benefits from one-time treatment with CTX001. While they’ve been followed for just nine months and four months, respectively, their painful flare-ups and once-routine need for blood transfusions stopped after getting the therapy. Both developed severe complications including infections that were deemed unrelated to the gene-editing treatment...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.